BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 ...
COPENHAGEN, Denmark I 19, 2024 I Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for ...
SAN DIEGO, CA, USA & EDMONTON, Canada I 19, 2024 I Aegis Life, Inc. (Aegis) and its partner Entos® Pharmaceuticals (Entos), announced today that ...
LONDON, UK and CAMBRIDGE, MA, USA I September 19, 2024 I Beacon Therapeutics Holdings Limited ('Beacon' or 'the Company'), a leading ophthalmic gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback